Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 9/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.38 |
| ▸ | CTRC | Q99895 | 4/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5866307 | 0.89 | KEAP1 (0.43) | KEAP1NFE2L2TSHRPPARDPPARA | |
| SCHEMBL5866177 | 0.86 | F2 (0.54) | F2KEAP1NFE2L2HCRTR2TSHR | |
| SCHEMBL5866157 | 0.85 | F2 (0.41) | F2PPARDPPARAMMP1MMP9 | |
| SCHEMBL5866153 | 0.85 | F2 (0.42) | F2KEAP1NFE2L2PPARDPPARA | |
| SCHEMBL5866179 | 0.85 | F2 (0.44) | F2KEAP1NFE2L2HCRTR2TSHR | |
| SCHEMBL5866129 | 0.84 | F2 (0.40) | F2PPARDPPARAMMP1MMP9 | |
| SCHEMBL5866230 | 0.83 | F2 (0.39) | F2PPARDPPARAPRSS2CTRC | |
| SCHEMBL5866244 | 0.82 | HCRTR2 (0.43) | F2KEAP1NFE2L2HCRTR2TSHR | |
| SCHEMBL5866249 | 0.80 | F2 (0.54) | F2HCRTR2PRSS2CTRC | |
| SCHEMBL5866390 | 0.77 | KEAP1 (0.53) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074820-B2 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| WO-2002083112-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH HOLDINGS CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-0917528-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| US-20020040043-A1 | Amidino derivatives and their use as thrombin inhibitors | ANTONSSON THOMAS (SE) | 2002-04-04 | — | — | US | disclosed |
| US-6221898-B1 | ANTICOAGULANTS | ASTRA AKTIEBOLAG (SE) | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040043-A1 | Amidino derivatives and their use as thrombin inhibitors | SERPINC1, F2, SERPINE1 | F2 2/4885KEAP1 4086/4885NFE2L2 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.